Autonomic Technologies

Apneon is an early stage medical device company developing devices for the treatment of sleep apnea.

Linguaflex is a medical device company with a patent pending technology to treat obstructive sleep apnea. LinguaFlex's LTR is implanted and designed to be comfortable, therefore addressing the lack of compliance as an issue in the successful treatment of OSA.

Neuromonics is an Australian company that has developed an FDA approved device for treatment of tinnitus over a six month process with 2 hours of use per day.

AllTranz aims to provide relief from chronic pain to patients outside the hospital setting.

Stealth mode medical device company developing devices for drug delivery. Monterey Devices submitted a patent on device for buffering anesthetics.

Beta-O2 Technologies is a biomedical company developing a proprietary implantable bioreactor, the ßAir. The company's flagship product is called the ßAir Bio-artificial Pancreas. It is in development as a treatment and potential cure for type 1 diabetes (T1D). ßAir was first designed to address the main problems of the otherwise successful procedures in which islets of Langerhans (i.e. pancreatic endocrine cells) are transplanted in diabetic patients, such as the need for life-long immunosuppressive pharmacological treatment and limited functionality of the transplanted islets over time due to an insufficient oxygen supply. The company's second pipeline product is the ßAir Bio-artificial Adrenal for the treatment of adrenocortical insufficiency and other stress-related disorders. This product is currently at the pre-clinical stage of development.